The goal of the Minority Core is to optimize minority participation in clinical trials conducted by ADCS investigators. To accomplish this we will continue our service specific activities of assisting investigators to minimize barriers to minority enrollment by reviewing protocols before initiation and providing translations for new instruments as needed. In addition we will develop new outreach strategies in minority communities using a range of media including ratio, video and print. Other strategies including identifying a nationally recognized spokesperson to raise awareness, visibility and credibility of clinical trial research to minority audiences. Our focus will expand beyond disease treatment studies to the topic of disease prevention. A part of this effort we will use attitude survey techniques to assess willingness to participate in primary and secondary prevention trials for AD. Pilot programs to provide education and information to overcome attitudes that create barriers to participation will be evaluated and the most successful programs will be developed for implementation at ADCS participation will be evaluated and the most successful programs will be developed for implementation at ADCS sites. We will also continue to provide training support and mentorship to sites with potential to recruit minority patients. We plan to identify new sites located in minority areas and work with their staff to train them in clinical trial methodology. Finally using our expanded minority data set we will continue to answer questions about clinical and medical outcomes, access to resources for care and services, and patterns of concomitant illnesses and treatment. This information will direct our trial design and guide our future recruitment efforts to maximize minority involvement in clinical research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG010483-12S1
Application #
6655729
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2002-09-15
Project End
2003-06-30
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Columbia University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10017
Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications